A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB3912 Tablets in Combination With Fulvestrant Injection± TQB3616 Capsules in Patients With Locally Advanced or Metastatic HR-positive and HER2-negative Breast Cancer
Latest Information Update: 28 May 2025
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; TQB 3912 (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 21 May 2025 Status changed from not yet recruiting to recruiting.
- 04 May 2025 Planned initiation date changed from 1 Mar 2025 to 1 May 2025.
- 04 Mar 2025 New trial record